The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial
Abstract
BACKGROUND: Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. This study was conducted to assess the efficacy and safety of olanzapine in treating psychosis and/or agitation/aggression in patients with AD. METHODS: A multicenter, double-blind, placebo-controlled, 6-week study was conducted in 206 elderly US nursing home residents with AD who exhibited psychotic and/or behavioral symptoms. Patients were randomly assigned to placebo or a fixed dose of 5, 10, or 15 mg/d of olanzapine. The primary efficacy measure was the sum of the Agitation/Aggression, Hallucinations, and Delusions items (Core Total) of the Neuropsychiatric Inventory-Nursing Home version. RESULTS: Low-dose olanzapine (5 and 10 mg/d) produced significant improvement compared with placebo on the Core Total (-7.6 vs -3.7 [P<.001] and -6.1 vs -3. 7 [P =.006], respectively). Core Total improvement with olanzapine, 15 mg/d, was not significantly greater than placebo. The Occupational Disruptiveness score, reflecting the impact of patients' psychosis and behavioral disturbances on the caregiver, was significantly reduced in the 5-mg/d olanzapine group compared with placebo (-2.7 vs -1.5; P =.008). Somnolence was significantly more common among patients receiving olanzapine (25.0%-35.8%), and gait disturbance occurred in those receiving 5 or 15 mg/d (19.6% and 17.0%, respectively). No significant cognitive impairment, increase in extrapyramidal symptoms, or central anticholinergic effects were found at any olanzapine dose relative to placebo. CONCLUSION: Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
(1987) · PubMed · Cited by 1,147
The spectrum of behavioral changes in Alzheimer's disease
Mega, M. S., Cummings, J. L., Fiorello, T., & Gornbein, J. (1996) · Neurology · doi:10.1212/wnl.46.1.130 · Cited by 1,115
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J., Brecher, M., & The Risperidone Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0207 · Cited by 741
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Overview of depression and psychosis in Alzheimer's disease
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.577 · Cited by 682
A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia
Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1990.tb02407.x · Cited by 650
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
De Deyn, P. P., Rabheru, K., Rasmussen, A., Bocksberger, J. P., Dautzenberg, P. L. J., Eriksson, S., & Lawlor, B. A. (1999) · Neurology · doi:10.1212/wnl.53.5.946 · Cited by 615
Kaufer, D. I., Cummings, J. L., Christine, D., Bray, T., Castellon, S., Masterman, D., MacMillan, A., Ketchel, P., & DeKosky, S. T. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb02542.x · Cited by 606
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Wood, S., Cummings, J. L., Hsu, M.-A., Barclay, T., Wheatley, M. V., Yarema, K. T., & Schnelle, J. F. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00010 · Cited by 489
Psychosis of Alzheimer's Disease and Related Dementias: Diagnostic Criteria for a Distinct Syndrome
Jeste, D. V., & Finkel, S. I. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00004 · Cited by 394
Antipyrine metabolism in man: Influence of age, alcohol, caffeine, and smoking
Vestal, R. E., Norris, A. H., Tobin, J. D., Cohen, B. H., Shock, N. W., & Andres, R. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184425 · Cited by 318
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.11.1438 · Cited by 253
Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
Cummings, J. L., & Kaufer, D. (1996) · Neurology · doi:10.1212/wnl.47.4.876 · Cited by 251
Devanand, D. P., Marder, K., Michaels, K. S., Sackeim, H. A., Bell, K., Sullivan, M. A., Cooper, T. B., Pelton, G. H., & Mayeux, R. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1512 · Cited by 236
The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials
Gillings, D., & Koch, G. (1991) · Drug Information Journal · doi:10.1177/009286159102500311 · Cited by 228
Bymaster, F. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00146-7 · Cited by 200
Quetiapine, A Novel Antipsychotic: Experience in Elderly Patients With Psychotic Disorders
McManus, D. Q., Arvanitis, L. A., Kowalcyk, B. B., & The Seroquel Trial 48 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0504 · Cited by 161
Pharmacokinetics in the aged: A review
Triggs, E. J., & Nation, R. L. (1975) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059473 · Cited by 158
Resident Behavior and Staff Distress in the Nursing Home
Everitt, D. E., Fields, D. R., Soumerai, S. S., & Avorn, J. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb02702.x · Cited by 155
Drug Prescribing for Elderly Patients
Chutka, D. S., Evans, J. M., Fleming, K. C., & Mikkelson, K. G. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.7.685 · Cited by 106
Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease
Soo Borson, B., & Raskind, M. A. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.17s · Cited by 105
Devanand, D. P., Sackeïm, H. A., Brown, R. P., & Mayeux, R. P. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440036018 · Cited by 104
Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 102
Nursing home statistical yearbook
Cowles, C. (1995) · Medical Entomology and Zoology · Cited by 78
Clozapine in Older Patients With Psychosis and Behavioral Disruption
Salzman, C., Vaccaro, B., Lieff, J. D., & Weiner, A. (1995) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199500310-00004 · Cited by 62
Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers
Wood, S. A., Cummings, J. L., Barclay, T. R., Hsu, M.-A., Allahyar, M., & Schnelle, J. F. (1999) · Aging & Mental Health · doi:10.1080/13607869956208 · Cited by 55
Reisberg, ., Ferris, S. H., de Leon, M. J., et al. (1989) · PubMed · Cited by 51
Girling, D. M., & Berríos, G. E. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.157.6.888 · Cited by 50
Bymaster, F. P., & Falcone, J. F. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00037-6 · Cited by 44
Assessment of Behavioral Symptoms in Alzheimer Disease
Patterson, M. B., & Bolger, J. P. (1994) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199404000-00002 · Cited by 40
Aging and drug disposition — Pharmacodynamics
Crooks, J. (1983) · Journal of Chronic Diseases · doi:10.1016/0021-9681(83)90047-4 · Cited by 39
Pharmacodynamic Basis for Altered Drug Action in the Elderly
Roberts, J., & Türner, N. (1988) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30769-9 · Cited by 38
Sweet, R. A., Akil, M., Mulsant, B. H., Ulrich, R. F., Pasternak, R. E., & Zubenko, G. S. (1998) · Journal of Neuropsychiatry · doi:10.1176/jnp.10.1.68 · Cited by 14
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Metadata
- Authors
- Street, J. S.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2000-10-01
- Volume
- 57
- Issue
- 10
- Pages
- 968
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1867692464
- Cited by
- 590
- References
- 45
- FWCI
- 39.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.